Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31812554

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Jan
First author
Geoerger B

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):13-14. doi: 10.1016/S1470-2045(19)30803-4.
    note
    Source null
    related pmid
    31812553
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Mar;21(3):e126. doi: 10.1016/S1470-2045(20)30077-2.
    note
    Source null
    related pmid
    32135110
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Mar;21(3):e127. doi: 10.1016/S1470-2045(20)30105-4.
    note
    Source null
    related pmid
    32135111
    relationship
    Comment in
  4. citation
    Ann Transl Med. 2020 Sep;8(17):1112. doi: 10.21037/atm.2020.04.54.
    note
    Source null
    related pmid
    33145331
    relationship
    Comment in

Authors and identifiers

  1. name
    Geoerger B
    type
    Author
  2. name
    Kang HJ
    type
    Author
  3. name
    Yalon-Oren M
    type
    Author
  4. name
    Marshall LV
    type
    Author
  5. name
    Vezina C
    type
    Author
  6. name
    Pappo A
    type
    Author
  7. name
    Laetsch TW
    type
    Author
  8. name
    Petrilli AS
    type
    Author
  9. name
    Ebinger M
    type
    Author
  10. name
    Toporski J
    type
    Author
  11. name
    Glade-Bender J
    type
    Author
  12. name
    Nicholls W
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Geoerger B
    type
    Author
  2. name
    Kang HJ
    type
    Author
  3. name
    Yalon-Oren M
    type
    Author
  4. name
    Marshall LV
    type
    Author
  5. name
    Vezina C
    type
    Author
  6. name
    Pappo A
    type
    Author
  7. name
    Laetsch TW
    type
    Author
  8. name
    Petrilli AS
    type
    Author
  9. name
    Ebinger M
    type
    Author
  10. name
    Toporski J
    type
    Author
  11. name
    Glade-Bender J
    type
    Author
  12. name
    Nicholls W
    type
    Author
bibliography ids
  1. nci-bib-6feb2d1f39812fa155ea8589
book metadata
content sha256
b98b48679694b592d3823e5e8db83ae48690c8b8ab3d6b94d656cf66239d04b3
document type
citation
dois
  1. 10.1016/S1470-2045(19)30671-0
electronic publication date
display
2019 Dec 4
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31812554
immutable id
pubmed:31812554@b98b48679694b592d3823e5e8db83ae48690c8b8ab3d6b94d656cf66239d04b3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
121-133
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):13-14. doi: 10.1016/S1470-2045(19)30803-4.
    note
    Source null
    related pmid
    31812553
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Mar;21(3):e126. doi: 10.1016/S1470-2045(20)30077-2.
    note
    Source null
    related pmid
    32135110
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Mar;21(3):e127. doi: 10.1016/S1470-2045(20)30105-4.
    note
    Source null
    related pmid
    32135111
    relationship
    Comment in
  4. citation
    Ann Transl Med. 2020 Sep;8(17):1112. doi: 10.21037/atm.2020.04.54.
    note
    Source null
    related pmid
    33145331
    relationship
    Comment in
outcomes validated
false
pmid
31812554
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
9f099ca97e1abb8889af5beff39c06ccf288c22a5c8f094d313d2bdee8f9c417
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Jan
precision
month
year
2020
publication types
  1. Clinical Trial, Phase I
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31812554/
title
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.

Preserved source evidence · Not medical advice